Overview

* Myriad Genetics Q3 2025 revenue declines 4% yr/yr, beats analyst expectations

* Adjusted operating income for Q3 beats analyst estimates

* Company recently entered into strategic collaboration with SOPHiA GENETICS for liquid biopsy CDx testing

Outlook

* Myriad Genetics ( MYGN ) reaffirms full-year 2025 revenue guidance of $818 mln to $828 mln

* Gross margin for 2025 expected between 69.5% and 70.0%

* Adjusted EPS for 2025 projected between $(0.02) and $0.02

Result Drivers

* HEREDITARY CANCER GROWTH - Hereditary cancer testing revenue and volume grew 3% and 11% yr/yr, respectively

* STRATEGIC COLLABORATION - Entered collaboration with SOPHiA GENETICS to develop liquid biopsy CDx testing solution

* PHARMACOGENOMICS DECLINE - Revenue impacted by UnitedHealthcare's discontinuation of coverage for GeneSight

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $205.70 $204.89

Revenue mln mln (13

Analysts

)

Q3 -$0.0078

Adjusted 5 (13

EPS Analysts

)

Q3 EPS -$0.29

Q3 Net -$27.40

Income mln

Q3 Gross 69.90%

Margin

Q3 Beat $4.10 $133,130

Adjusted mln (8

Operatin Analysts

g Income )

Q3 $140 mln

Adjusted

Operatin

g

Expenses

Q3 $167.10

Operatin mln

g

Expenses

Q3 -$23.30

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 8 "hold" and 3 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Myriad Genetics Inc ( MYGN ) is $6.50, about 23.7% below its October 31 closing price of $8.04

* The stock recently traded at 99 times the next 12-month earnings vs. a P/E of 51 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)